drugset / Trial / NCT00439673
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of the trial is to assess the activity of the combined use of Valproic Acid (VPA)in combination with 5-Azacytidine (5-Aza C) in the treatment of MDS. Activity will be evaluated as percentage of patients achieving complete or partial remission.
Timeline
- Start
- 2007-05
- Primary completion
- 2010-07
- Completion
- 2010-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | — | — |
| Subject | Tretinoin | Small molecule | — | — |
| Subject | Valproic Acid | Small molecule | — | — |